submit to the journals

Renal Cancer Journal Articles, Videos And Insights

Renal Cancer: FEATURED Articles

flipper_slider

Renal Cancer: Latest Articles

Renal Cancer: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
Eisai and Merck Announce Latest Data on Lenvatinib and Pembrolizumab for Multiple Cancer Types at ASCO 2018 Katrina Mountfort
Medical Writer, Touch Medical Media, UK
Insight
ASCO 2017 Insight – High Dose Interleukin 2 Katrina Mountfort, Touch Medical Media, Reading, UK
Insight
The Role of Interleukin in the Treatment of Malignant Melanoma and Renal Cell Carcinoma Katrina Mountfort, Freelance Medical Writer for Touch Medical Media, UK

Renal Cancer: FEATURED VIDEOS

Editor's choice

Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for investigating radical resection of metastases followed by sorafenib in advanced renal cell carcinoma? (0:11) 2. Could you tell us a little about the RESORT study design? (1:15) 3. What were the findings of the study? (1:50) 4. Why do you think sorafenib has no effect on relapse-free survival? (3:17) 5. What will be the next steps in this clinical investigation? (4:06) Speaker disclosures: Giuseppe Procopio serves on the advisory board for Bayer, Bristol-Myers Squibb, Ipsen, Novartis and Pfizer. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Arnaud Méjean from the HEGP, Université Paris Descartes and ADHP in Paris, France, discusses the place of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma, and how this approach may change based on the results of the CARMENA trial. 1. What is the current role of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma? (0:11) 2. How did the advent of targeted therapies affect the use of cytoreductive nephrectomy? (0:32) 3. Could you tell us a little about the design of the CARMENA clinical trial? (0:58) 4. What were the findings of this study? (2:02) 5. What patients are most likely to benefit from this approach? (3:08) Speaker disclosures: Arnaud Méjean has nothing to disclose in relation to this video interview. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Renal Cancer: Latest Videos

Video List based on Category on Node Page

Latest Videos

Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for...
Arnaud Méjean from the HEGP, Université Paris Descartes and ADHP in Paris, France, discusses the place of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma, and how this approach may change based on the results of the CARMENA trial. 1. What...
Editorial board member Ulka Vaishampayan from the Karmanos Cancer Center, Wayne State University, Detroit, MI, US, talks to us about the place of personalized therapy in patients with advance renal cancer and the potential role of X4P-001 in treatment paradigms in the near future. 1. What are...
Prof Thomas Powles, (Barts Health, London, UK) talks to ecancertv at ASCO GU 2015 about the use of dual TORC1 and 2 inhibitors, such as AZD2014, in the treatment of renal cancer.
Dr Naomi Balzer-Haas, (ECOG-ACRIN Cancer Research Group, Philadelphia, USA) talks to ecancertv at ASCO GU 2015 about the initial results from the phase III ASSURE trial.
At the Thirteenth International Kidney Cancer Symposium, Dr JianJun Gao (The University of Texas MD Anderson Cancer Center, TX) discusses papillary renal cell carcinoma (pRCC) and prospective immunotherapy.

LATEST TWEETS

Conference Highlights